Infants with blood cancer particularly suffer from the side effects of chemotherapy and have a poor prognosis. This highlights the need for new and innovative treatment approaches. Dr. Klusmann's research team and others have recently revealed the importance of areas in the genome for the development of blood cancer that were previously considered as “junk”. These areas are extremely large and can serve as a unique therapeutic target. Dr. Klusmann will investigate those areas and evaluate therapeutic option to overcome current obstacles in the treatment of infants with blood cancer.

Awarded at Martin-Luther-Universitat Halle-Wittenberg and transferred to Goethe University Frankfurt.

Through this partnership with German Childhood Cancer Foundation, proceeds from St. Baldrick's events in Germany fund life-saving research in Germany. St. Baldrick's is proud to partner with German Childhood Cancer Foundation and has been doing so since 2015.

Rhabdomyosarcomas are the most common soft-tissue cancers in children and adolescents. Current treatments are often ineffective, and researchers need new ideas to treat this cancer. Dr. Hettmer has developed a new model of pleomorphic rhabdomyosarcoma, and is using this to show that a protein (Gremlin 1) produced by rhabdomyosarcoma tumors could be important. She is investigating how Gremlin 1 changes rhabdomyosarcoma behavior and whether it can serve as a drug target. Awarded at Children's Hospital Boston and transferred to Charité Universitätsmedizin Berlin.

Through this partnership with Hilfe für krebskranke Kinder Frankfurt e.V, proceeds from St. Baldrick's events in Germany fund life-saving research in Germany. St. Baldrick's is proud to partner with Hilfe für krebskranke Kinder Frankfurt e.V and has been doing so since 2011.